I am including thyroid hormone medications as symptomatic therapies (as opposed to therapeutic) frequently given to patients with Wilson’s Temperature Syndrome who would frequently respond better to proper thyroid hormone therapy (especially the WT3 protocol). This is to underscore the fact that the choice of thyroid hormone medication must, in every case, be based on the underlying cause of DTSF suspected in each individual patient. As we discussed previously, there are different causes of DTSF and they are not all best treated in the same way. Even patients having the same cause of DTSF, should be treated on a tailored individual case basis. For example, even though three different people each drive separately from the same apartment building to the same grocery store by car, their paths should be individualized depending on red lights, green lights, roads taken, curbs, pedestrians, traffic, lane changes, and other important factors. Some patients may be suffering from two causes of DTSF at the same time. Patients suffering from DTSF frequently do not respond completely to the thyroid hormone regimen they are being prescribed because it may not be adequately addressing the underlying cause or causes. Likewise, if the symptoms do improve to an extent, they may return after treatment has been discontinued; whereas, they might remain persistently improved if the proper thyroid hormone treatment is prescribed.

One such example is the frequent situation that occurs when a patient suffering from Graves’ Disease (hyperthyroidism) undergoes complete removal or destruction of the thyroid gland in order to correct this, sometimes life-threatening, over-active thyroid gland problem. After the removal or destruction of the gland, the patient will be dependent on thyroid hormone medication for life. Such patients are frequently started on T4 preparations. As one might imagine, however, developing a serious illness which results in the removal of one’s thyroid gland can be a rather stressful experience. Consequently, such patients may not satisfactorily convert the T4 medication they are given which can leave them with some very disturbing complaints of DTSF. Prior to developing Graves’ Disease such a patient may have been completely healthy without any problems or health complaints of any kind, then the patient develops symptoms of an overactive thyroid system for which the patient requires treatment. After treatment, the patient may be left with symptoms of underactive thyroid system function in spite of being treated with thyroid hormone medication. So, in spite of treatment, the patient is left with disturbing symptoms of DTSF which were not present before the patient’s development of Graves’ Disease. However, with the WT3 protocol, the former Graves’ Disease patient’s DTSF, due to Wilson’s Temperature Syndrome (impaired conversion of the T4 medication prescribed), may be corrected. Once the T4 to T3 conversion impairment is corrected with the WT3 protocol, the Graves’ Disease patient can frequently be switched back to T4 therapy and enjoy persistent correction of the symptoms of DTSF, and once again return to feeling much the way he or she felt prior to developing Graves’ Disease.